RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Auris Medical Holding Stock

Auris Medical Holding ROCE 2024

Auris Medical Holding ROCE

0

Ticker

EARS

ISIN

BMG070252017

WKN

A2PJN3

In 2024, Auris Medical Holding's return on capital employed (ROCE) was 0, a 0% increase from the 0 ROCE in the previous year.

Auris Medical Holding Aktienanalyse

What does Auris Medical Holding do?

Auris Medical Holding Ltd is a biopharmaceutical company that was founded in 2013 and is headquartered in Zug, Switzerland. The company specializes in the development and marketing of products in the field of hearing and hearing impairment. The history of Auris Medical Holding Ltd began with the founding of the company by Thomas Meyer and Daniel J. Salomon, both of whom had extensive experience in the biotech industry and investment banking. The company went public on the NASDAQ stock exchange in 2014 and has since expanded its business steadily. Auris Medical's business model is based on the development of innovative therapies and medications for disorders in the ENT field. The company focuses on the needs of patients with hearing and hearing impairment due to neurosensory disorders. In this area, there are currently only a few approved therapies, which represents a significant unmet medical need. Auris Medical divides its activities into two divisions: the development of clinical therapies and the marketing of products for the treatment of tinnitus and hearing loss. In the field of clinical therapies, the company specializes in the development of medications for restoring hearing. Among other things, Auris Medical is working on the development of AM-111, a treatment for acute inner ear damage that can lead to sudden hearing loss. Auris Medical also operates its own distribution chain, which offers products for the treatment of tinnitus and hearing loss. These products are marketed under the name Tinnitool and include devices for relieving tinnitus and hearing loss. The company also offers audiology services to perform individual audiological evaluations. Overall, Auris Medical Holding Ltd has a wide range of products aimed at the needs of patients with hearing and hearing impairment. From medications to symptom relief products to diagnostic services, the company is able to address various aspects of the health issue. As an innovative company, Auris Medical Holding Ltd invests heavily in research and development of new therapies and medications. The company collaborates with leading experts in the field of hearing and hearing impairment to improve its technologies and products. Additionally, the company aims to expand into further regions to reach a broader patient base. In summary, Auris Medical Holding Ltd is an emerging company in the field of hearing and hearing impairment. With a wide product portfolio tailored to the needs of patients, the company invests in research and development to develop new therapies and medications. Through its innovation and strong partnerships in the field of hearing and hearing impairment, the company plans to establish itself as a leading company in this field. Auris Medical Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Auris Medical Holding's Return on Capital Employed (ROCE)

Auris Medical Holding's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Auris Medical Holding's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Auris Medical Holding's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Auris Medical Holding’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Auris Medical Holding stock

What is the ROCE (Return on Capital Employed) of Auris Medical Holding this year?

The ROCE of Auris Medical Holding is 0 undefined this year.

How has the ROCE (Return on Capital Employed) of Auris Medical Holding developed compared to the previous year?

The ROCE of Auris Medical Holding has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Auris Medical Holding?

A high Return on Capital Employed (ROCE) indicates that Auris Medical Holding has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Auris Medical Holding?

A low ROCE (Return on Capital Employed) can indicate that Auris Medical Holding has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Auris Medical Holding impact the company?

An increase in the ROCE of Auris Medical Holding can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Auris Medical Holding affect the company?

A decrease in ROCE of Auris Medical Holding can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Auris Medical Holding?

Some factors that can affect Auris Medical Holding's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Auris Medical Holding so important for investors?

The ROCE of Auris Medical Holding is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Auris Medical Holding take to improve the ROCE?

To improve the ROCE, Auris Medical Holding can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Auris Medical Holding pay?

Over the past 12 months, Auris Medical Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Auris Medical Holding is expected to pay a dividend of 0 CHF.

What is the dividend yield of Auris Medical Holding?

The current dividend yield of Auris Medical Holding is .

When does Auris Medical Holding pay dividends?

Auris Medical Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Auris Medical Holding?

Auris Medical Holding paid dividends every year for the past 0 years.

What is the dividend of Auris Medical Holding?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Auris Medical Holding located?

Auris Medical Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Auris Medical Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Auris Medical Holding from 9/22/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Auris Medical Holding pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Auris Medical Holding in the year 2023?

In the year 2023, Auris Medical Holding distributed 0 CHF as dividends.

In which currency does Auris Medical Holding pay out the dividend?

The dividends of Auris Medical Holding are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Auris Medical Holding

Our stock analysis for Auris Medical Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Auris Medical Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.